A Lesson In Confidence Amid Development Hurdles: How Lilly Has Talked About Donanemab

 
• By Derrick Gingery
  
Alzheimer's disease
Donanemab will require an advisory committee meeting before the FDA makes a decision on the application. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards